Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging
Keith A. Johnson(Brigham and Women's Hospital), Jeremy Carmasin(Harvard University), Jacqueline Maye(Harvard University), Carl Sadowsky(Nova Southeastern University), Daniel Skovronsky(Eli Lilly (United States)), Eric M. Reiman(Alzheimer's Association), Adam Fleisher(Banner Alzheimer’s Institute), Mark A. Mintun(Washington University in St. Louis), Christopher Gidicsin(Harvard University), Michel J. Pontecorvo, Ming‐Chi Lu(University of California, San Francisco), Christopher M. Clark(Institute on Aging), Marwan N. Sabbagh(Cleveland Clinic), Alan Carpenter, P. Murali Doraiswamy(Alzheimer’s Disease Neuroimaging Initiative), R. Edward Coleman(Japan Society for the Promotion of Science), Reisa A. Sperling(Harvard University), Abhinay D. Joshi
Cited by 265
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k